Jonathan Milner releases presentation to Abcam plc shareholders, outlining reasons to reject Danaher's bid and strategic vision for the Company
- Notable expects to initiate trading on the Nasdaq Capital Market under ticker symbol “NTBL” effective at market open on October 17 -
Visit link:
Notable Labs Closes Merger Transaction With VBL Therapeutics
Jonathan Milner Issues Statement Responding to ISS Report
More here:
Jonathan Milner Issues Statement Responding to ISS Report
Partnership supports execution of a large phase 2 global study to evaluate efficacy and safety of recombinant human plasma gelsolin (rhu-pGSN) for moderate-to-severe ARDS.
MBX 2109 was generally well-tolerated across all dosing cohorts
Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET Call scheduled for Tuesday, October 17, 2023 at 8:00 a.m. ET
See the original post here:
Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures
— 52-week results from the Phase 3 PaTHway Trial showed that the skeletal dynamics of adult patients with chronic hypoparathyroidism treated with TransCon PTH trended toward a new steady state closer to age-appropriate norms
See the original post:
Ascendis Pharma Presents TransCon™ PTH (palopegteriparatide) Phase 3 52-Week Skeletal Dynamics Data at ASBMR 2023
Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment Naxitamab-based chemo-immunotherapy significantly improves long-term outcomes when administered early during the course of treatment
See original here:
Y-mAbs Announces Publication in Cancers
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will host a live webcast at 8:00 a.m. ET / 2:00 p.m. CEST on Monday, October 23, 2023 to review interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) presented at the European Society of Medical Oncology Congress (ESMO) 2023.
See the rest here:
Harpoon Therapeutics to Host Webcast Reviewing HPN328 Interim Data Presented at ESMO Congress 2023 on October 23, 2023
BUFFALO, N.Y., Oct. 16, 2023 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII) (the “Company”), a leading biotechnology company dedicated to improving health with reduced nicotine tobacco, hemp/cannabis and hops advanced plant technologies, today announced that it intends to offer and sell in a “best efforts” public offering shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase shares of common stock. All of the shares of common stock (or common stock equivalents) and warrants in the offering are to be offered by the Company. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Read the rest here:
22nd Century Announces Proposed Public Offering